Micro-elimination of hepatitis C virus infection in the rural and remote areas of Taiwan – A multi-center collaborative care model

Introduction: Taiwan has several hepatitis C virus (HCV) hyper-endemic areas. We aimed to evaluate the effectiveness and safety of a collaborative HCV care system with an outreach decentralized strategy among the resource-constrained rural/remote areas of Taiwan. Methods: The pilot study was conduct...

Full description

Bibliographic Details
Published in:	Journal of Microbiology, Immunology and Infection
Main Authors:	Ching-Chu Lo, Wei-Yi Lei, Ying-Che Huang, Jow-Jyh Hwang, Chen-Yu Lo, Chien-hung Lin, Hsu-sheng Cheng, Yee-Tam Liao, Po-Cheng Liang, Meng-Jau Chiou, Ming-Jong Bair, Chia-Yen Dai, Ming-Lung Yu
Format:	Article
Language:	English
Published:	Elsevier 2023-08-01
Subjects:	HCV DAA SVR Rural area
Online Access:	http://www.sciencedirect.com/science/article/pii/S1684118223000336

Similar Items

Perspective of the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication in the post-DAA era: Correspondence to editorial on “Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication”
by: Chung-Feng Huang, et al.
Published: (2024-10-01)

Long-Term Hepatic and Extrahepatic Outcomes of Chronic Hepatitis C Patients After Sofosbuvir-Based Treatment (LONGHEAD Study)
by: Chung-Feng Huang, et al.
Published: (2025-04-01)

Critical role of triglycerides for adiponectin levels in hepatitis C: a joint study of human and HCV core transgenic mice
by: Ming-Ling Chang, et al.
Published: (2021-08-01)

Worsening of Controlled Attenuation Parameter and Metabolic Profile After HCV Cure in People with HIV as a Sign of Steatosis
by: Alessia Siribelli, et al.
Published: (2025-06-01)

Impact of interferon-free regimens in patients with chronic HCV and successfully ablated HCC
by: Amr Maged Mahmoud Rasheed, et al.
Published: (2025-02-01)

Predictors of hepatocellular carcinoma recurrence associated with the use of direct‐acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort study
by: Masahito Nakano, et al.
Published: (2019-05-01)

Efficacy and safety of directly acting antiviral drugs in HCV patients with HIV in liver transplantation: A meta-analysis
by: Tian Zeng, et al.
Published: (2023-01-01)

Direct-acting antivirals for patients with chronic hepatitis C and hepatocellular carcinoma in Taiwan
by: Chen-Ta Chi, et al.
Published: (2021-06-01)

Correspondence on Letter regarding “Toward hepatitis C virus elimination using artificial intelligence”
by: Ming-Ying Lu, et al.
Published: (2024-04-01)

Steatotic liver disease in chronic hepatitis C related hepatocellular carcinoma: Inflictor or bystander?: Correspondence to editorial on “Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan”
by: Chung-Feng Huang, et al.
Published: (2025-01-01)

Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan
by: Chung-Feng Huang, et al.
Published: (2024-10-01)

A people-centered decentralized outreach model toward HCV micro-elimination in hyperendemic areas: COMPACT study in SARS Co–V2 pandemic
by: Ching-I Huang, et al.
Published: (2023-06-01)

Hepatitis C Elimination in Egypt: Story of Success
by: Asmaa Gomaa, et al.
Published: (2024-08-01)

Improvement of patient-reported outcomes in patients achieving sustained virologic response with direct-acting antivirals for hepatitis C virus infection
by: Chih-Hsun Yi, et al.
Published: (2022-08-01)

Sustained virological response in HCV patients receiving antiviral treatment at a teaching centre of northern India
by: Astha, et al.
Published: (2025-03-01)

Impact of HCV eradication by directly acting antivirals on glycemic indices in chronic hepatitis C patients -a nationwide Taiwan HCV registry
by: Tyng-Yuan Jang, et al.
Published: (2025-08-01)

Evaluation of alcohol use behavior among patients cured through HCV elimination program in Georgia
by: Maia Butsashvili, et al.
Published: (2024-06-01)

Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents
by: Ghweil AA, et al.
Published: (2019-04-01)

Real-Life Data of Chronic Hepatitis C Patients Treated with Direct-Acting Oral Antivirals: A Single-Center Study
by: Umut Devrim Binay, et al.
Published: (2023-05-01)

Real world experience with the all-oral interferon free regimen for the treatment of chronic hepatitis c virus infection in the Lebanese population
by: Jowana Saba, et al.
Published: (2018-02-01)

Decoupled Glucose and Lipid Metabolic Recovery after Viral Clearance in Direct-Acting Antiviral-Treated HCV Patients: A 3-Year Prospective Cohort Study
by: Heng Lee, et al.
Published: (2021-10-01)

Persistence of hepatitis C virus in peripheral blood mononuclear cells of patients who achieved sustained virological response following treatment with direct-acting antivirals is associated with a distinct pre-existing immune exhaustion status
by: Sylwia Osuch, et al.
Published: (2025-06-01)

Long-term renal function alterations in hepatitis C patients with SVRs: Impacts of therapies and mixed cryoglobulinemia
by: Ming-Ling Chang, et al.
Published: (2024-03-01)

Genetic Subtypes and Natural Resistance Mutations in HCV Genotype 4 Infected Saudi Arabian Patients
by: Mariantonietta Di Stefano, et al.
Published: (2021-09-01)

HCV eradication in people living with HIV: the final countdown?
by: A. De Vito, et al.
Published: (2021-02-01)

Impact of HCV elimination on metabolism markers in people living with HIV
by: Andrés Deza de la Casa, et al.
Published: (2025-05-01)

Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication
by: Chung-Feng Huang, et al.
Published: (2024-07-01)

DAA treatment for HCV reduce risk of hepatocellular carcinoma: a 10-years follow-up study based on Chinese patients with hepatitis C
by: Xiaobo Zhu, et al.
Published: (2024-10-01)

Updated Clinical Guidelines on the Management of Hepatitis C Infection in Children
by: Chaowapong Jarasvaraparn, et al.
Published: (2024-02-01)

Elimination of HCV replication machinery early after antiviral treatment with DAA monitored by multimodal microscopy
by: Castro Victoria, et al.
Published: (2024-01-01)

Reply to correspondence on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy”
by: Seren M. Gedallovich, et al.
Published: (2024-10-01)

PATIENTS WITH HAEMOGLOBINOPATHIES AND CHRONIC HEPATITIS C: A REALLY DIFFICULT TO TREAT POPULATION IN 2016?
by: Kalliopi Zachou, et al.
Published: (2017-01-01)

The Role of RASs /RVs in the Current Management of HCV
by: Konstantinos Malandris, et al.
Published: (2021-10-01)

B-type natriuretic peptide (BNP) in HCV-positive Egyptian patients: the impact of HCV eradication on plasma BNP levels
by: Ali Nada, et al.
Published: (2021-07-01)

Efficacy of Different Combinations of Direct-Acting Antivirals Against Different Hepatitis C Virus-Infected Population Groups: An Experience in Tertiary Care Hospitals in West Bengal, India
by: Sagnik Bakshi, et al.
Published: (2025-02-01)

Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital
by: Nahed Mohammed Hawsawi, et al.
Published: (2023-01-01)

HCV Cascade of Care in HIV/HCV Co-Infected Individuals: Missed Opportunities for Micro-Elimination
by: Christos Thomadakis, et al.
Published: (2024-05-01)

Performance of Elecsys<sup>®</sup> HCV Duo Immunoassay for Diagnosis and Assessment of Treatment Response in HCV Patients with or without HIV Infection
by: Prooksa Ananchuensook, et al.
Published: (2024-09-01)

Efficacy and Safety of Adding Ribavirin to Sofosbuvir-Based Direct-Acting Antivirals (DAAs) in Re-Treating Non-Genotype 1 Hepatitis C—A Systematic Review and Meta-Analysis
by: Shahd Hamran, et al.
Published: (2025-04-01)

Combination of Sofosbuvir-Ledipasvir and Sofosbuvir- Daclatasvir for Treatment HCV Patients in Indonesia
by: Andri Sanityoso Sulaiman, et al.
Published: (2023-12-01)